The EU HTA Regulation: joint clinical assessments from 2025, and what they change for launch timing

What changed

Marketing authorisation has been European for decades; deciding whether a medicine is worth paying for has stayed national, done twenty-seven times in twenty-seven ways. The HTA Regulation, in force since January 2022 and applying in stages from 12 January 2025, adds one European step: a joint clinical assessment (JCA) of a new medicine’s clinical evidence, produced by the member states together through a coordination group and published by the Commission.

The scope grows in three steps:

• From 12 January 2025: new medicines for cancer, and advanced therapy medicinal products, authorised centrally.
• From 13 January 2028: orphan medicines.
• From 13 January 2030: all other new centrally authorised medicines (new active substances and, in defined cases, new indications).

Generics, biosimilars and hybrids are not in scope, and nor are nationally authorised products.

What a JCA is, and is not

The assessment runs in parallel with the EMA’s: the company submits a dossier against questions (populations, comparators, outcomes) scoped by the member states, assessors from two countries draft the report, and it is published within about thirty days of the Commission’s authorisation decision. It analyses the clinical evidence relative to the comparators the member states asked for; it says nothing about added value, cost-effectiveness or price, which remain national. Member states must give the report “due consideration” in their own assessments and may not ask the company again for what the report already contains; they may still ask for the economic evidence they need. The Regulation also provides joint scientific consultations before pivotal trials, so that companies can design evidence for both regulators and payers.

What it changes for the launch calendar

In law, nothing. The authorisation date, the data-protection clocks and the SPC are untouched, and so is the day a product may be sold.

In practice, the national pricing and reimbursement step that follows authorisation is the one the Regulation is aimed at. Where a member state’s assessment used to start from scratch after the Commission decision, it can now start from a published report; the intention is shorter national timelines, especially in smaller countries that lacked assessment capacity. Whether the gap between authorisation and reimbursed availability actually shortens will be visible in the launch data over the next few years, country by country, and it will shorten unevenly.

Evidence becomes public and comparative. The report, with the comparators and the populations the member states chose, is published for everyone, including competitors, payers in non-EU markets and, in time, the courts. A product’s evidence position in Europe is now a single document.

Sequencing pressure. Because the scoping is EU-wide, companies cannot tailor the comparator to each country; the trial design has to anticipate the whole Union’s questions, which pushes evidence planning earlier and makes the joint scientific consultation worth the effort.

What it does not touch

Generic and biosimilar entry dates (the exclusivity clocks); parallel trade (prices and licences are national and unchanged); national price negotiations, confidential discounts and tenders; and the UK, which is outside the Regulation and runs its own NICE, SMC and AWMSG assessments.

What it means, by role

For an originator or licensor, the JCA is a launch workstream with its own deadlines, dossier and comparator fights, starting now for oncology and advanced therapies and by 2030 for everything.

For a launch planner of generics or biosimilars, nothing changes in the timeline; the published reports are a new, free source of comparative clinical evidence on the reference product.

For a buyer or payer, the reports are the evidence base national decisions will cite, and the dates above say when each class of product starts to carry one.

For a parallel trader, no effect on licences or exclusivity; if national reimbursement becomes faster in some countries, the price differentials that drive trade may narrow sooner after launch.

MPA Search records the authorisation and exclusivity dates that the JCA sits beside; the regulatory-changes notes will record the first years of practice as the reports appear.